Diabetes drug shows promise for dangerous low sodium condition

NCT ID NCT04447911

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the diabetes drug empagliflozin (Jardiance) can safely raise low sodium levels in people with certain conditions like SIADH, liver failure, or kidney failure. About 172 adults with chronic low sodium will receive either the drug or a placebo for up to 30 days. The goal is to see if the drug works better than current treatments like fluid restriction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EUVOLEMIC HYPONATREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyponatremia inappropriate ADH syndrome kidney failure liver failure nephrogenic syndrome of inappropriate antidiuresis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPONATREMIA KIDNEY FAILURE LIVER FAILURE SIADH

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois (CHUV)
RECRUITING

Lausanne, Canton of Vaud, 1011, Switzerland
Erasmus Universität Medisch Centrum Rotterdam, Department of Internal Medicine
RECRUITING

Rotterdam, 3015, Netherlands
Kantonsspital Luzern
RECRUITING

Lucerne, 6000, Switzerland
Spitalzentrum Biel
RECRUITING

Biel, 2502, Switzerland
University Hospital Basel
RECRUITING

Basel, 4031, Switzerland
University Hospital of Würzburg, med. Poliklinik
RECRUITING

Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.